HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

AZ 11645373

InChIKey: VQEHBLGYANQWEA-UHFFFAOYSA-N

Also Known As:

2,4-Thiazolidinedione, 3-(1-(((3'-nitro(1,1'-biphenyl)-4- yl)oxy)methyl)-3-(4-pyridinyl)propyl)-; AZ-11645373; AZ11645373

Networked: 3 relevant articles (1 outcomes, 1 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Organic Chemicals: 133
- Sulfur Compounds: 278
  - Thiazoles: 392
    - AZ 11645373: 3
Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Azoles: 2138
    - Thiazoles: 392
      - AZ 11645373: 3

Experts

1.	Drummond, Grant R: 1 article (10/2019)
2.	Kirby, Francis J: 1 article (10/2019)
3.	Lawlor, Kate E: 1 article (10/2019)
4.	Mansell, Ashley: 1 article (10/2019)
5.	Rainczuk, Kate: 1 article (10/2019)
6.	Rosli, Sarah: 1 article (10/2019)
7.	Tate, Michelle D: 1 article (10/2019)
8.	Bradding, P: 1 article (08/2009)
9.	Seward, E P: 1 article (08/2009)
10.	Vial, C: 1 article (08/2009)

Related Diseases

1.	Human Influenza (Influenza) 10/01/2019 - "Our study demonstrates that the anti-inflammatory drugs probenecid and AZ11645373, which have documented pharmacokinetics and safety profiles in humans, are effective at dampening hyperinflammation and severe influenza disease providing potentially new therapeutic strategies for treating severe or pathogenic IAV infections." 10/01/2019 - "Intranasal therapeutic treatment of mice displaying severe influenza disease with probenecid or AZ11645373 reduced pro-inflammatory cytokine production, cellular infiltrates in the lung, and provided protection against disease. "
2.	Infections 10/01/2019 - "Our study demonstrates that the anti-inflammatory drugs probenecid and AZ11645373, which have documented pharmacokinetics and safety profiles in humans, are effective at dampening hyperinflammation and severe influenza disease providing potentially new therapeutic strategies for treating severe or pathogenic IAV infections." 10/01/2019 - "We tested two existing drugs, probenecid and AZ11645373, to target P2X7 receptor signalling and dampen NLRP3 inflammasome responses during severe IAV infection. "
3.	Brain Contusion 08/01/2023 - "Adult male Sprague-Dawley rats were subjected to cortical contusion injury (CCI) and randomly assigned to injury and drug treatment conditions, as follows: i) No surgical intervention (naïve group); ii) dimethyl sulfoxide treatment after CCI (CCI-control group); iii) 5-BDBD (antagonist of P2X4 receptor) treatment after CCI (CCI-5-BDBD group); iv) CCI-AZ11645373 (antagonist of P2X7 receptor) treatment after CCI (CCI-AZ11645373 group); v) or 5-BDBD and AZ11645373 treatment after CCI (CCI-5-BDBD + AZ11645373 group). "
4.	type 2C Congenital disorder of glycosylation 08/01/2009 - "A P2X7-like non-desensitizing current in response to high concentrations of ATP (1-5 mM) was also seen in both cell types (96% LAD2, n= 24; 54% HLMCs, n= 24) which was antagonized by AZ11645373 (1 microM). "

Related Drugs and Biologics

1.	Probenecid (Benemid)
2.	Cytokines
3.	Purinergic P2X7 Receptors
4.	Purinergic P2X4 Receptors
5.	Inflammasomes
6.	Dimethyl Sulfoxide (DMSO)
7.	Adenosine Triphosphate (ATP)